Grail Class Action Lawsuit Initiated
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing shareholders who purchased stock between May 13, 2025, and February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by top executives.
- False Statements Allegations: The lawsuit claims that Grail misrepresented its ability to significantly reduce late-stage cancer rates in the NHS-Galleri trial while concealing adverse facts that undermined the likelihood of achieving this outcome, misleading investors about the company's prospects.
- Stock Price Plunge: On February 19, 2026, Grail announced that a statistically significant reduction in late-stage cancers was not observed, leading to a stock price drop of over 50%, resulting in substantial losses for investors.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek appointment as lead plaintiff, representing other shareholders in pursuit of damages, highlighting the importance of protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 60.160
Low
38.00
Averages
60.86
High
83.71
Current: 60.160
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail Class Action Lawsuit Initiated
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing shareholders who purchased stock between May 13, 2025, and February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by top executives.
- False Statements Allegations: The lawsuit claims that Grail misrepresented its ability to significantly reduce late-stage cancer rates in the NHS-Galleri trial while concealing adverse facts that undermined the likelihood of achieving this outcome, misleading investors about the company's prospects.
- Stock Price Plunge: On February 19, 2026, Grail announced that a statistically significant reduction in late-stage cancers was not observed, leading to a stock price drop of over 50%, resulting in substantial losses for investors.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek appointment as lead plaintiff, representing other shareholders in pursuit of damages, highlighting the importance of protecting investor rights.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. faces a class action lawsuit for failing to disclose weakening customer orders and poor financial results during the period from April 18, 2024, to April 16, 2026, with a lead plaintiff deadline of July 27, 2026, potentially damaging the company's reputation and stock price.
- PicS N.V. Lawsuit: PicS N.V. is being sued for not disclosing deficiencies in its credit evaluation procedures and declining customer credit quality during the period from January 27, 2026, to June 5, 2026, with a lead plaintiff deadline of August 4, 2026, which may impact the company's future financing capabilities and market trust.
- Verra Mobility Lawsuit: Verra Mobility Corporation faces a class action lawsuit for not disclosing its reliance on a contract with Avis during the period from February 24, 2026, to May 26, 2026, with a lead plaintiff deadline of August 4, 2026, potentially leading to downward revisions in performance expectations and stock price volatility.
- Grail, Inc. Lawsuit: Grail, Inc. is being sued for management's overly optimistic confidence in clinical trial results during the period from May 13, 2025, to February 19, 2026, with a lead plaintiff deadline of August 4, 2026, which may affect the company's future financing and market confidence.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc., specifically targeting investors who purchased securities between May 13, 2025, and February 19, 2026, and reminding them to apply for lead plaintiff status by August 4, 2026, to represent other investors in the federal securities class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, the stock price plummeted from $101.53 to $50.21 per share, marking a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- False Statements Revealed: Grail executives had repeatedly expressed confidence in the success of the NHS-Galleri trial, claiming its design was sufficient to demonstrate a statistically significant reduction, while concealing the fact that the trial period was inadequate to achieve the primary endpoint, misleading investors.
- Legal Rights Reminder: Faruqi & Faruqi encourages all investors who purchased Grail stock during the class period and suffered losses to contact them to discuss their legal rights, ensuring that investors can secure their rightful compensation in any future claims.
See More
GRAIL, Inc. Faces Class Action Lawsuit Over Securities Fraud
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc., alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors advised to apply as Lead Plaintiff by August 4, 2026.
- Stock Price Plunge: Following GRAIL's announcement on February 19, 2026, that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV, the stock price fell over 50%, causing significant losses for investors.
- Legal Consultation Information: Investors are encouraged to contact Pomerantz LLP via email or phone for more information regarding the class action, and they should provide their share purchase details and contact information to facilitate case handling.
- Firm Background: Pomerantz LLP is a prominent class action law firm with over 85 years of experience, focusing on securities, antitrust, and corporate misconduct litigation, having recovered millions in damages for class members.
See More
Class Action Filed Against Grail, Inc. Over Misleading Statements
- Class Action Initiated: Robbins LLP has announced a class action lawsuit on behalf of investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026, alleging misleading statements regarding early cancer detection that resulted in economic losses for shareholders.
- Stock Price Plunge: Following the announcement of the lawsuit, Grail's stock price plummeted from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, representing a dramatic decline of approximately 50.55% in a single trading day, indicating severe market concerns about the company's financial health.
- Misleading Statements: The lawsuit alleges that Grail, Inc. made false and misleading statements regarding the potential effectiveness of its NHS-Galleri product, leading investors to purchase shares at artificially inflated prices, ultimately resulting in significant economic losses.
- Legal Implications: Investors may participate in the class action through Robbins LLP, with the lead plaintiff acting on behalf of other class members to guide the litigation process, highlighting the importance of corporate governance and executive accountability in seeking compensation for affected shareholders.
See More
Investigation Announced for Grail, Inc. Securities Violations
- Legal Investigation Launched: The Law Offices of Howard G. Smith announced an investigation into Grail, Inc. (NASDAQ:GRAL) regarding potential violations of federal securities laws, indicating significant legal risks that may undermine investor confidence.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the NHS-Galleri trial did not show statistically significant reductions in Stage III-IV cancer, Grail's stock price plummeted by 50.5% to close at $50.21 per share, resulting in substantial losses for investors.
- Investor Losses: The drastic decline in stock price has left investors facing potential financial losses, prompting the Law Offices of Howard G. Smith to encourage affected investors to reach out for possible claims, highlighting the likelihood of legal action.
- Legal Consultation Channels: Investors are urged to contact the law firm via phone or email to learn about their legal rights, demonstrating the company's commitment to transparency and investor support amidst legal challenges.
See More
Grail Class Action Lawsuit Initiated
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing shareholders who purchased stock between May 13, 2025, and February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by top executives.
- False Statements Allegations: The lawsuit claims that Grail misrepresented its ability to significantly reduce late-stage cancer rates in the NHS-Galleri trial while concealing adverse facts that undermined the likelihood of achieving this outcome, misleading investors about the company's prospects.
- Stock Price Plunge: On February 19, 2026, Grail announced that a statistically significant reduction in late-stage cancers was not observed, leading to a stock price drop of over 50%, resulting in substantial losses for investors.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek appointment as lead plaintiff, representing other shareholders in pursuit of damages, highlighting the importance of protecting investor rights.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. faces a class action lawsuit for failing to disclose weakening customer orders and poor financial results during the period from April 18, 2024, to April 16, 2026, with a lead plaintiff deadline of July 27, 2026, potentially damaging the company's reputation and stock price.
- PicS N.V. Lawsuit: PicS N.V. is being sued for not disclosing deficiencies in its credit evaluation procedures and declining customer credit quality during the period from January 27, 2026, to June 5, 2026, with a lead plaintiff deadline of August 4, 2026, which may impact the company's future financing capabilities and market trust.
- Verra Mobility Lawsuit: Verra Mobility Corporation faces a class action lawsuit for not disclosing its reliance on a contract with Avis during the period from February 24, 2026, to May 26, 2026, with a lead plaintiff deadline of August 4, 2026, potentially leading to downward revisions in performance expectations and stock price volatility.
- Grail, Inc. Lawsuit: Grail, Inc. is being sued for management's overly optimistic confidence in clinical trial results during the period from May 13, 2025, to February 19, 2026, with a lead plaintiff deadline of August 4, 2026, which may affect the company's future financing and market confidence.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc., specifically targeting investors who purchased securities between May 13, 2025, and February 19, 2026, and reminding them to apply for lead plaintiff status by August 4, 2026, to represent other investors in the federal securities class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, the stock price plummeted from $101.53 to $50.21 per share, marking a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- False Statements Revealed: Grail executives had repeatedly expressed confidence in the success of the NHS-Galleri trial, claiming its design was sufficient to demonstrate a statistically significant reduction, while concealing the fact that the trial period was inadequate to achieve the primary endpoint, misleading investors.
- Legal Rights Reminder: Faruqi & Faruqi encourages all investors who purchased Grail stock during the class period and suffered losses to contact them to discuss their legal rights, ensuring that investors can secure their rightful compensation in any future claims.
See More
GRAIL, Inc. Faces Class Action Lawsuit Over Securities Fraud
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc., alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors advised to apply as Lead Plaintiff by August 4, 2026.
- Stock Price Plunge: Following GRAIL's announcement on February 19, 2026, that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV, the stock price fell over 50%, causing significant losses for investors.
- Legal Consultation Information: Investors are encouraged to contact Pomerantz LLP via email or phone for more information regarding the class action, and they should provide their share purchase details and contact information to facilitate case handling.
- Firm Background: Pomerantz LLP is a prominent class action law firm with over 85 years of experience, focusing on securities, antitrust, and corporate misconduct litigation, having recovered millions in damages for class members.
See More
Class Action Filed Against Grail, Inc. Over Misleading Statements
- Class Action Initiated: Robbins LLP has announced a class action lawsuit on behalf of investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026, alleging misleading statements regarding early cancer detection that resulted in economic losses for shareholders.
- Stock Price Plunge: Following the announcement of the lawsuit, Grail's stock price plummeted from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, representing a dramatic decline of approximately 50.55% in a single trading day, indicating severe market concerns about the company's financial health.
- Misleading Statements: The lawsuit alleges that Grail, Inc. made false and misleading statements regarding the potential effectiveness of its NHS-Galleri product, leading investors to purchase shares at artificially inflated prices, ultimately resulting in significant economic losses.
- Legal Implications: Investors may participate in the class action through Robbins LLP, with the lead plaintiff acting on behalf of other class members to guide the litigation process, highlighting the importance of corporate governance and executive accountability in seeking compensation for affected shareholders.
See More
Investigation Announced for Grail, Inc. Securities Violations
- Legal Investigation Launched: The Law Offices of Howard G. Smith announced an investigation into Grail, Inc. (NASDAQ:GRAL) regarding potential violations of federal securities laws, indicating significant legal risks that may undermine investor confidence.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the NHS-Galleri trial did not show statistically significant reductions in Stage III-IV cancer, Grail's stock price plummeted by 50.5% to close at $50.21 per share, resulting in substantial losses for investors.
- Investor Losses: The drastic decline in stock price has left investors facing potential financial losses, prompting the Law Offices of Howard G. Smith to encourage affected investors to reach out for possible claims, highlighting the likelihood of legal action.
- Legal Consultation Channels: Investors are urged to contact the law firm via phone or email to learn about their legal rights, demonstrating the company's commitment to transparency and investor support amidst legal challenges.
See More
